The Effect of Therapeutic Plasma Exchange on COVID-19 Therapy

References (7)

1. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020;111:102452. Choi S, Kim MC, Kwon JS, Kim JY, Lee KH, Kim SH. Case Report: use of plasma exchange followed by convalescent plasma therapy in a critically ill patient with severe fever and thrombocytopenia syndrome-associated encephalopathy: cytokine/chemokine concentrations, viral loads, and antibody responses. Am J Trop Med Hyg. 2018;99:1466-1468.
2. Cheng CW, Hendrickson JE, Tormey CA, Sidhu D. Therapeutic Plasma Exchange and Its Impact on Drug Levels: An ACLPS Critical Review. Am J Clin Pathol. 2017;148:190-198.
3. Hausfater P, Cacoub P, Assogba U, Lebon P, Piette JC. Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis. Nephron. 2002;91:627-630.
4. Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:155-166. Wolters Kluwer UpToDate®. Last accessed date: 20.08.2020. Accessed 20/08/2020. Available from: https://www.uptodate.com/
5. Deng P, Zhong D, Yu K, Zhang Y, Wang T, Chen X. Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans. Antimicrob Agents Chemother. 2013;57:1743-1755.
6. Szefler SJ, Ebling WF, Georgitis JW, Jusko WJ. Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. Eur J Clin Pharmacol. 1986;30:323-329.
7. Nguyen TH, Guedj J, Anglaret X, Laouenan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentre F, JIKI study group. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. Plos Negl Trop Dis. 017;11:e0005389. Agency EM (2020) Summary on compassionate use: Remdesivir Gilead https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf